Tell us the market and what you stock. Aravis establishes what is already registered there, who supplies it today, and where demand is going unmet, then sets a range of 2,186 molecules against it and returns the molecules worth filing in priority order, with the documentation route for each.
Registered importers, licensed distributors and pharmacy chains with demonstrated presence in their market. The authority you file with, the channels you sell into and the approximate scale of your current import all shape what the analysis can tell you.
We review every enquiry and respond where there is a portfolio fit.
How long the analysis takes follows from its scope, and the scope is set in the first conversation.
Every enquiry is acknowledged when it is submitted.
Aravis makes contact to establish what the analysis needs to cover: the market, the therapy areas in scope, and the range you already stock.
The molecules worth filing, in priority order, with the documentation route for each. The timeline is agreed once the scope is known.
Aravis has traded since 1987 and has cleared 138 registrations with four drug authorities.